Key opportunities include non-surgical treatments, outpatient procedures, and global expansion, particularly in Asia-Pacific. Major players are focusing on immuno-oncology advancements. Cutaneous ...

The global recurrent head and neck cancer squamous cell carcinoma market is experiencing robust growth, projected to expand from $3.32 billion in 2025 to $3.55 billion in 2026 at ...

Alpha Tau’s IMPACT trial is expected to enroll up to 30 patients across the U.S., Canada, and Israel, focusing on patients ...

Todd Schlesinger, MD, discusses how new immunotherapies and multidisciplinary care are reshaping treatment approaches for patients with advanced skin cancers. This content was developed independently ...

Recent updates to the National Comprehensive Cancer Network (NCCN) guidelines for cutaneous squamous cell carcinoma (CSCC) ...

Please provide your email address to receive an email when new articles are posted on . The indication applies to adults with metastatic or locally advanced disease who are not candidates for curative ...

Cervical squamous cell carcinoma is one of the predominant histological subtypes of cervical cancer, with significant morbidity and mortality globally. Its management increasingly relies on the ...

A new preclinical study found that inhibiting the enzyme LSD1 can activate the skin’s immune system and suppress tumor growth ...

Comparing metagenomic profiles of the skin microbiome in immunosuppressed patients and those at high and low risk for cutaneous squamous cell carcinoma (SCC) revealed distinct expansions in fungal and ...

A new study by investigators from Mass General Brigham uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment. This therapy is the first ...